Blog

Jul 31, 2024, 08:54

Akhil Kapoor: Intensifying Chemo in advanced Gastric Cancer doesn’t improve survivals

Akhil Kapoor, Associate Professor and Medical Oncology at TMH Varanasi, shared a post on X about a recent paper titled “Docetaxel-oxaliplatin-capecitabine/5 fluorouracil (DOC/F) followed by docetaxel versus Oxaliplatin-Capecitabine/5 fluorouracil (CAPOX/mFOLFOX-7) in HER2 negative advanced gastric cancers” published on JNCI.

Authors: Vikas Ostwal, Anant Ramaswamy, Prabhat Bhargava, Biswajit Dubashi, Anuj Gupta, Akhil Kapoor, Sujay Srinivas, Omshree Shetty, Poonam Jadhav, et al.

“Our Multicenter study led by Vikas Ostwal and Anant Ramaswamy published in JNCI.

Intensifying Chemo in advanced Gastric Cancer doesn’t improve survivals
Increases toxicities
More is NOT always better.

Genomic Profiling revealed:

Low incidence of microsatellite instability (1%)
High incidence of BRCA1 (7.5%) and BRCA2 (8.4%) somatic alterations. Implications??”

Source: Akhil Kapoor/X

Akhil Kapoor Anant Ramaswamy Anuj Gupta Biswajit Dubashi BRCA1 BRCA2 cancer JNCI Omshree Shetty OncoDaily Oncology Poonam Jadhav Prabhat Bhargava somatic alterations Sujay Srinivas Vikas Ostwal

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage